BRIEF—Samsung Biologics signs big money, big pharma deal

Korean company Samsung Biologics has signed a production agreement with an unidentified large US pharma corporation worth more than $1.06 billion.

According to a public disclosure, the deal will run to the end of 2030, though this date may be changed in the future.

Samsung Bio already has manufacturing agreements in place with other healthcare firms including Belgian drugmaker UCB and USA-based Baxter Healthcare.